Overview

Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

Status:
Terminated

Trial end date:
2016-03-22

Target enrollment:

Participant gender:

Summary

This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals